Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Intelligent Ultrasound Group plc    MED   GB00BN791Q39

INTELLIGENT ULTRASOUND GROUP PLC

(MED)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancials 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Medaphor : Patent Infringement Settlement and Trading update

01/26/2017 | 06:56am EST

MedaPhor Group plc

('the Group' or the 'Company')

Patent Infringement Settlement and Trading update

MedaPhor Group plc (AIM: MED), the global provider of advanced ultrasound training simulators for medical professionals, provides the following update on the patent infringement settlement and on trading for the year to 31 December 2016.

Patent infringement settlement

Further to the statement made by the Company on 16 December 2016, the Group subsidiaries, MedaPhor Limited and MedaPhor North America Inc. (collectively 'MedaPhor'), announce that MedaPhor and SonoSim Inc. and The Regents of the University of California have now formalized and executed their agreement on a patent license and patent infringement settlement. As a result, the lawsuit between the parties will be dismissed with prejudice.

Trading update

The Company reports that unaudited Group turnover for the year to 31 December 2016 grew by 50% to £3.3m (2015: £2.2m). Unaudited Global sales of ScanTrainer training simulators grew by 10% to £2.45m for the year to 31 December 2016. Following the acquisition of Inventive Medical Limited in August 2016, HeartWorks training simulators contributed approximately £0.85m to sales in the post-acquisition period.

The loss for the year before share based payment charges, but after the currently anticipated one-off costs of the SonoSim litigation and final settlement, is expected to be around £2.5m (2015: Loss, £1.5m).

Cash, at 31 December 2016 net of the anticipated litigation and settlement costs payable, was £1.4m.

The Board is encouraged by the sales growth achieved in 2016 despite the issues faced during the year. Following the resolution of the patent infringement action, the Board looks forward to achieving its growth targets for its US based business in FY 2017 and beyond.

This announcement contains inside informationwhich, prior to its disclosure, was inside information for the purposes of the Market Abuse Regulation(Article 7 of Regulation (EU) No 596/2014)

Enquiries:

MedaPhor Group plc

www.medaphor.com

Stuart Gall, CEO

Tel: +44 (0)29 2075 6534

Cenkos Securities

Tel: +44 (0)20 7397 8900

Bobbie Hilliam (Nominated Adviser)

Julian Morse (Corporate Broking)

Walbrook PR

Tel: +44 (0)20 7933 8780 or medaphor@walbrookpr.com

Paul McManus / Anna Dunphy

Mob: +44 (0)7980 541 893 / Mob: +44 (0)7876 741 001

Medaphor Group plc published this content on 26 January 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 26 January 2017 11:55:14 UTC.


© Publicnow 2017
All news about INTELLIGENT ULTRASOUND GROUP PLC
2020INTELLIGENT ULTRASOUND : Says GE Healthcare Machine Using Its Technology Granted..
DJ
2020INTELLIGENT ULTRASOUND : ISO13485 certification for medical devices
PU
2020INTELLIGENT ULTRASOUND : Growth & Innovation Forum 2020
PU
2018MEDAPHOR : Trading and IUL integration update
PU
2017MEDAPHOR : Innovate UK Grant Award
PU
2017MEDAPHOR : Director Appointment
PU
2017MEDAPHOR : wins first ScanTrainer customer in India
PU
2017MEDAPHOR : Result of Annual General Meeting
PU
2017MEDAPHOR : Grant of options
PU
2017MEDAPHOR : University of Hertfordshire achieves 100% transvaginal pass rate with..
PU
More news
Financials
Sales 2019 5,92 M 8,04 M 8,04 M
Net income 2019 -4,22 M -5,74 M -5,74 M
Net cash 2019 7,22 M 9,80 M 9,80 M
P/E ratio 2019 -4,23x
Yield 2019 -
Capitalization 41,1 M 55,8 M 55,8 M
EV / Sales 2018 1,23x
EV / Sales 2019 2,50x
Nbr of Employees 45
Free-Float 78,2%
Chart INTELLIGENT ULTRASOUND GROUP PLC
Duration : Period :
Intelligent Ultrasound Group plc Technical Analysis Chart | MED | GB00BN791Q39 | MarketScreener
Technical analysis trends INTELLIGENT ULTRASOUND GROUP PLC
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Managers and Directors
NameTitle
Stuart Arthur Gall Chief Executive Officer & Executive Director
Riccardo Pigliucci Non-Executive Chairman
Ian George Whittaker Chief Operating Officer & Executive Director
Helen Mary Kinsey Jones Group Finance Director & Director
Nicholas Sleep Executive Director & Chief Technology Officer